, Volume 2, Issue 3, pp 256-261

Treatment of the antiphospholipid antibody syndrome: Progress in the last five years?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains highintensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful “proving ground” of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.